Saturday 17 October 2026 Export IMTX’s income statement to Excel — free account

Immatics N.V.

Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024. In the quarter to June 2026, revenue grew 97.7%, EPS grew 19.7% and free cash flow fell 44.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.72 0.42 −5.88%

Follow IMTX

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: 6.75
Beneish M: −1.36
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 7.50

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.56%

Capital & Financial Ratios $m

Market Cap 1,070.00

Revenue 49.20

Net Income (237.04)

Free Cash Flow (240.08)

Net Debt (270.28)

Current Ratio 7.54

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.78)

P/S ratio 18.67

P/B ratio 1.98

Past 5Y EPS Growth —

This Y EPS Growth (12.12%)

Next Y EPS Growth (2.54%)

Next Y revenue growth (16.26%)

Next 5Y EPS Growth (0.06%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 72.68%

10-year low 10-year high

P/B against its own 10 years 11.65%

10-year low 10-year high

EV/Sales against its own 10 years 70.51%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	236	256	391	270
Receivables	4	6	7	7
Inventory	—	—	—	—
Other	245	419	172	222
	486	681	570	499

	2023	2024	2025	Q'26
Payables	27	22	21	39
ST’ Debt	—	—	—	—
Other	31	9	6	13
	169	74	49	66

Compound Annual Growth %

	10y	5y	3y
Sales	—	11.81%	(33.06%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	39.34%	34.60%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	11	—	—	—
’25	20	5	6	24	55
’24	33	20	56	60	169
’23	11	24	6	17	58
’22	115	18	15	33	182
’21	9	6	8	18	41
’20	8	8	9	14	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	(70)	—	—	—
’25	(36)	(47)	(55)	(62)	(200)
’24	(35)	(35)	(39)	(62)	(171)
’23	(25)	(8)	(33)	86	20
’22	122	52	(42)	(27)	105
’21	(20)	(24)	(21)	(32)	(97)
’20	0	(13)	(57)	(16)	(86)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(71)	—	—	—
’25	(39)	(49)	(56)	(63)	(208)
’24	(45)	(38)	(42)	(63)	(189)
’23	(30)	(19)	(40)	76	(14)
’22	121	51	(43)	(30)	99
’21	(21)	(26)	(23)	(34)	(103)
’20	0	(18)	(59)	(16)	(93)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.50)	(0.53)	—	—	—
’25	(0.35)	(0.66)	(0.49)	(0.34)	(1.82)
’24	(0.03)	(0.18)	(0.09)	0.48	0.15
’23	(0.28)	(0.35)	(0.35)	(0.32)	(1.30)
’22	1.52	(0.23)	(0.32)	(0.23)	0.58
’21	(0.41)	(0.46)	(0.51)	(0.30)	(1.75)
’20	(0.18)	(20.19)	(3.30)	18.88	(5.45)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	0.01	9.71	8.67	10.12	5.75	5.90	6.68	3.30	Analyst estimates 2026–2028 Powerpack
	High	—	—	9.80	11.16	17.48	18.42	13.60	13.14	13.77	12.41
People
People	Employees	—	—	2	2	198	255	293	343	423	407
	Revenue/emp, $m	—	—	1.89	9.22	0.16	0.16	0.62	0.17	0.40	0.13
Income, $m
Income, $m	Revenue	—	—	4	18	31	41	182	58	169	55
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(32)	(32)	(230)	(110)	44	(105)	23	(225)
	EBT margin, %	—	—	(858.22)	(176.09)	(734.70)	(268.49)	24.32	(179.63)	13.70	(411.13)
	Net income	—	0	(32)	(32)	(230)	(110)	40	(105)	16	(222)
	Depreciation	—	—	2	4	4	6	7	8	13	14
Per share, $
Per share, $	Revenue	—	—	0.11	0.56	0.65	0.65	2.71	0.73	1.59	0.45
	Earnings	—	—	(0.98)	(0.98)	(5.45)	(1.75)	0.59	(1.30)	0.15	(1.82)
	Cash flow	—	—	0.63	2.14	(1.78)	(1.54)	1.57	0.24	(1.62)	(1.63)
	Capex	—	—	(0.01)	(0.06)	(0.16)	(0.11)	(0.10)	(0.41)	(0.17)	(0.06)
	Free cash flow	—	—	0.61	2.08	(1.94)	(1.64)	1.47	(0.17)	(1.79)	(1.70)
	Book value	—	—	0.15	(1.23)	2.17	0.45	3.34	3.02	5.88	4.48
	Shares, m	—	—	33	33	48	63	67	81	106	122
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	11.43	0.00	39.50	0.00
	P/S	—	—	0.00	0.00	13.28	20.56	3.16	14.78	4.46	23.53
	P/B	—	—	6.13	0.00	4.97	29.70	2.57	3.54	1.21	2.35
	EV/Sales	—	—	0.00	0.00	7.96	16.73	2.30	10.73	2.94	16.36
	EV/FCF	—	—	0.00	3.39	(3.26)	(6.65)	4.24	(46.06)	(2.62)	(4.30)
Cash, $m
Cash, $m	Operating cash flow	—	—	21	71	(86)	(97)	105	20	(171)	(200)
	Capex	—	—	0	(2)	(8)	(7)	(6)	(33)	(18)	(8)
	Free cash flow	—	—	20	69	(93)	(103)	99	(14)	(189)	(208)
Balance, $m
Balance, $m	Working capital	—	—	1	55	178	68	285	317	608	522
	Total debt	—	—	—	4	28	43	34	—	—	—
	Net debt	—	—	(1)	(103)	(208)	(157)	(156)	(236)	(256)	(391)
	Shareholders’ equity	—	—	5	(41)	104	28	225	244	622	548
Returns, %
Returns, %	ROA	—	—	(43.13)	(22.54)	(117.79)	(47.88)	12.42	(21.39)	2.52	(31.99)
	ROIC	—	—	(565.68)	0.00	0.00	0.00	28.96	(961.55)	(7.14)	(82.33)
	ROE	—	—	106.81	176.20	(722.34)	(166.40)	31.24	(44.84)	3.80	(38.00)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
NBTX Nanobiotix S.A. - Sponsored ADR	$1.1B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%	Compare
REPL Replimune Group, Inc.	$1.1B	— (loss-making)	—	—	n/m	+5.04% (above 0%: growing)	0.00%	0.00%	Compare
IMTX Immatics N.V.	$1.1B	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)
JANX Janux Therapeutics, Inc.	$1.1B	— (loss-making)	— (loss-making)	+2,238.72% (above 0%: growing)	n/m	+150.57% (above 0%: growing)	100.00%	(308.66%)	Compare
MNKD MannKind Corporation	$1.0B	— (loss-making)	— (loss-making)	+42.92% (above 0%: growing)	n/m	−399.41% (below 0%: shrinking)	72.99%	(0.32%)	Compare
SVRA Savara Inc.	$973.9M	— (loss-making)	— (loss-making)	—	n/m	−14.05% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$1.1B	—	—	+42.92%	—	−60.27%	0.00%	0.00%

All 614 Biotechnology stocks →

Immatics N.V. (IMTX) key facts

Concern: Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024.
Immatics N.V. (IMTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IMTX traded at $6.72, a market capitalization of $1.1 billion.
Return on equity was −38.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 6.75 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.